Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence (ChanBan)

U.S. FDA Resources

Enrollment:	10
Study Start Date:	November 2008
Study Completion Date:	September 2010
Primary Completion Date:	September 2010 (Final data collection date for primary outcome measure)

Inclusion Criteria:

1. 18 years and up.
2. Smoked at least 10 cigarettes/day for at least 1 year.
3. English speaking and reading.

4. Females who are of childbearing potential must practice effective contraception and meet the following criteria:

   1. Are instructed to avoid pregnancy through 30 days after the last dose of study medication.
   2. Have a negative urine pregnancy test at baseline.
   3. Agree to use of the birth control methods listed: an oral contraceptive agent, an intrauterine device (IUD), an implantable contraceptive (e.g., Norplant), or an injectable contraceptive (e.g., Depo-Provera) for at least one month prior to entering the study and will continue its use through at least 30 days after the last dose of the study medication. A barrier method of contraception (e.g., condom or diaphragm with spermicide) while participating in the study and 30 days after the last dose of study medication.
5. Willingness to not use illicit drugs during study period including marijuana.

Exclusion Criteria:

1. Any unstable medical condition.
2. Unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months or an untreated cardiac dysrhythmia.
3. Personal history of seizures.
4. Closed head trauma with any loss of consciousness or amnesia in the last 5 years.
5. A history of closed head trauma with > 30 minutes of loss of consciousness or amnesia or resulting in skull fracture or subdural hematoma/brain contusion.
6. A history of psychosis, bipolar disorder, bulimia or anorexia nervosa.
7. Current depression as assessed by Center for Epidemiologic Studies Depression Scale (CES-D).
8. Medications that might affect the outcome measures of nicotine reward, cognition, anxiety, and stress will also be a basis for exclusion. These medications include psychotropic drugs (i.e., anti-psychotic, anti-depressant, anti-anxiety, or stimulant), anti- hypertensive agents (e.g., beta-blockers), and other drugs that can influence the outcome domains.
9. Active substance abuse other than nicotine.
10. Used an investigational drug within the last 30 days.
11. Are currently using a behavioral or pharmacologic tobacco treatment.
12. Use of bupropion or varenicline in the previous 30 days.
13. Current (past 14 days) use of antipsychotic or antidepressant medications.
14. An allergy to bupropion or varenicline.
15. Untreated hypertension or baseline systolic blood pressure > 180 or diastolic > 100.
16. Impaired kidney function (creatinine clearance < 30).
17. Having plans to leave the immediate geographical area within 2 months.

18. Unwillingness or inability to give written informed consent.

    -

Pfizer

Tobacco Use Research Center 

Tobacco Nicotine Smoking Varenicline Bupropion Human laboratory study

Stress tolerance Startle response Cognitive assessment Progressive ratio Motivation

Tobacco Use Disorder Substance Withdrawal Syndrome Substance-Related Disorders Mental Disorders Nicotine Varenicline Bupropion Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Nicotinic Agonists

Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Dopamine Uptake Inhibitors Dopamine Agents Neurotransmitter Uptake Inhibitors